What Ampharco does

Ampharco U.S.A (Công ty Cổ phần Dược phẩm Ampharco U.S.A) is a privately held Vietnamese pharmaceutical manufacturer and distributor founded in 1969 as Thai Van Labs and operating from Nhon Trach 3 Industrial Park, Dong Nai, with a branch in Ho Chi Minh City. The company operates two manufacturing plants: Factory A, which has held WHO-GMP certification since 2005, and Factory B, which received EU-GMP certification in March 2025, together producing approximately one billion galenic units per year across tablets, film-coated and controlled-release tablets, soft capsules, powders, liquids, and topical dosage forms. Its portfolio spans 15 therapeutic categories including cardiovascular, respiratory, antibiotics, anti-inflammatory, neurology-musculoskeletal, urology-reproductive health, topical products, endocrine, infusion, and health supplements, organized under house brands such as AMFAGOLD, SOS, MAXX, NIDAL, and VICRAAPC.

The company generates revenue through three streams: proprietary pharmaceutical manufacturing and sales to Vietnamese pharmacies, wholesalers, and hospitals; contract manufacturing under OEM and technology-transfer agreements, most notably a 2025 deal with France's Servier covering roughly half of Servier's Vietnam-distributed volume across five medicines for diabetes, cardiovascular disease, and venous insufficiency, and an ongoing Sanofi OEM relationship dating to 2012 covering 120+ transferred SKUs; and GSP-certified warehousing services offered to third parties. Distribution is nationwide across all provinces of Vietnam through a mix of direct pharmacy supply, wholesale (including with DKSH), hospital tenders, and field-marketing to healthcare professionals, supported by over 10,000m² of GSP-certified warehousing in Dong Nai and the HCMC branch. The company employs 300+ staff and positions itself as a long-tenured, GMP-compliant partner for both Vietnamese healthcare access and multinational technology transfer into Vietnam.

Name

Ampharco

Legal name

Công ty Cổ phần Dược phẩm Ampharco U.S.A

Website

https://ampharcousa.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

11–50 employees

Short description

Ampharco U.S.A is a privately held Vietnamese pharmaceutical manufacturer with over 50 years of history, operating WHO-GMP and EU-GMP certified plants producing roughly one billion galenic units yearly across 15 therapeutic categories and distributing nationwide to pharmacies, wholesalers, and hospitals.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Drugs and Druggists' Sundries Merchant Wholesalers (424210)

SIC

Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Full-Line Pharmaceutical Wholesalers (HLAIAJAA)

akta.pro secondary industries

Specialty Pharmaceutical Distributors (HLAIAJAB), Pharmaceutical & Life Sciences Warehousing (GDP-Compliant) (TLAIACAD)

Keywords

• Pharmaceutical manufacturing
• Generic medicines production
• Health supplements
• Contract pharmaceutical manufacturing
• GSP-certified warehousing

Headquarters

HQ city

Ho Chi Minh City

HQ country

Vietnam

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing and Sales: Manufacturing and distribution of pharmaceutical products across 15 therapeutic categories including cardiovascular, respiratory, anti-inflammatory, antibiotics, and health supplements. Products sold through pharmacies and hospital tenders across Vietnam.
2. Contract Manufacturing (Technology Transfer): Technology transfer manufacturing agreement with Servier (France) for production of original brand medicines at EU-GMP certified facility. Ampharco will manufacture approximately 50% of Servier's products distributed in Vietnam.
3. Warehousing Services: GSP-certified warehouse leasing services for pharmaceutical storage, offering both normal and cold condition storage (2-8°C) with capacity over 10,000m².

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Ampharco U.S.A manufactures and distributes a comprehensive portfolio of pharmaceutical products across 15 therapeutic categories including cardiovascular, respiratory, anti-inflammatory, antibiotics, antivirals, neurology-musculoskeletal, urology, digestive, endocrine, infusion, antiallergics, topical, bone-joint, and health supplements. The company operates two GMP-certified manufacturing plants in Vietnam (WHO-GMP Factory A since 2005 and EU-GMP Factory B since March 2025) with over 1 billion galenic units annual capacity, and provides GSP-certified warehousing services across a nationwide distribution network.

Product overview

Ampharco U.S.A Pharmaceutical Joint Stock Company operates as a diversified pharmaceutical manufacturer with over 50 years of experience. The company produces a comprehensive portfolio spanning 15 product groups including: Antiallergics, Antibiotics, Anti-inflammatory-Analgesics-Antipyretics, Antivirals, Bone and Joint, Cardiovascular, Digestive System, Endocrine, Infusion, Neurology-Musculoskeletal, Respiratory, Topical Products, Urology-Reproductive Health, Cosmetics, and Health Supplements. Key product lines include AMFAGOLD health supplements (3B, 4FLEX, ACTIVE JOINT, C 1000, CORDY PLUS, DERMA, E-NATURAL, G2 PLUS, GINKGO, HEPA), MAXXNEURO neurology products, MAXXVITON piracetam products, VICRAAPC sildenafil products, SOSCough herbal products, and various cardiovascular, antibiotic, and infusion medications. The company operates WHO-GMP and EU-GMP certified manufacturing facilities with a GSP-certified warehousing system.

Differentiator

Problem solved

Functional benefit

Brands

• AMFAGOLD: Health supplements product line including AMFAGOLD 3B, AMFAGOLD 4FLEX, AMFAGOLD ACTIVE JOINT, AMFAGOLD C 1000, AMFAGOLD CORDY PLUS, AMFAGOLD DERMA, AMFAGOLD E-NATURAL, AMFAGOLD G2 PLUS, AMFAGOLD GINKGO, AMFAGOLD HEPA
• SOS
• MAXX
• NIDAL
• VICRAAPC
• USATRYPSIN
• AMINIC
• Amphabio

Products and services

• AMFAGOLD Health Supplements Comprehensive health supplement line covering vitamins, joint care, liver support, skin nourishment, and cerebral circulation. Sold through pharmacies and wholesalers nationwide in Vietnam.
• SOS OTC Pharmaceutical Line Over-the-counter pharmaceutical products covering topical, respiratory, antipyretic, antiallergic, and other self-care conditions. Includes the top-selling SOSLac G3 topical brand. Sold through pharmacies and retail distribution.
• MAXX Specialty Pharmaceutical Line Specialty prescription pharmaceutical line covering neurology (Pregabalin, Piracetam, Donepezil, Levetiracetam, Mirtazapine, Gabapentin), musculoskeletal (Baclofen), and other therapeutic areas. Distributed to hospitals via tenders and through pharmacy channels.
• VICRAAPC Erectile Dysfunction Treatment Sildenafil 50mg and 100mg film-coated tablets for the treatment of erectile dysfunction in adult males. Sold via pharmacy distribution in Vietnam.
• NIDAL Anti-Inflammatory Analgesics Anti-inflammatory and analgesic pharmaceutical products in multiple formulations including NIDAL PLUS, NIDAL FORT, NIDAL DAY, NIDAL-FLEX 50, and NEO-NIDAL. Distributed through hospital tenders and retail pharmacy channels in Vietnam.
• AMINIC Infusion Solution Amino acid IV infusion solution used for plasma protein reduction and treatment of malnutrition cases. Sold to hospitals via tender processes.
• Cardiovascular Pharmaceutical Products Cardiovascular pharmaceutical products including AmloAPC (hypertension treatment) and ZarelAPC 15 (Rivaroxaban 15mg tablets). Distributed via hospital tenders and pharmacy channels.
• Antibiotic Pharmaceuticals (ZIMAXAPC) Antibiotic pharmaceutical products including ZIMAXAPC 500 (Azithromycin 500mg film-coated tablets) for treatment of bacterial infections. Sold via hospital tenders and pharmacy distribution.
• AmphaBio COVID-19 Test Kit AmphaBio HT high-throughput PCR COVID-19 diagnostic test kit capable of detecting most known SARS-CoV-2 variants. Licensed by the Vietnam Ministry of Health and supplied to government and healthcare institutions.
• Servier Original Brand Medicine Contract Manufacturing Contract manufacturing and technology transfer services for Servier (France), producing approximately 50% of Servier's original brand medicines distributed in Vietnam, covering diabetes, cardiovascular, and venous insufficiency treatments at the EU-GMP certified Factory B.
• GSP-Certified Pharmaceutical Warehousing Services Leasing of over 10,000m² of GSP-certified warehouse facilities for pharmaceutical storage with both ambient and cold-chain (2-8°C) conditions. Located at Nhon Trach 3 Industrial Park, Dong Nai Province, with expansion to five warehouses planned by 2026.

Named customers4 records

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered flagship, core and minor.

• Servier (Les Laboratoires Servier)flagshipStrategic or Co-development Partner · 16 April 2025Technology transfer and manufacturing agreement for production of original brand medicines. Ampharco will manufacture approximately 50% of Servier's products distributed in Vietnam. Servier transferred technology for five key medicines used in treatment of diabetes, cardiovascular diseases, and venous insufficiency. Agreement signed with witnessed by French Consul General and Vietnamese government officials.
• SanoficoreStrategic or Co-development PartnerLong-term partnership for OEM manufacturing. Transferred over 120 SKUs to Sanofi in 2012 (99% of existing drug portfolio at that time). Ongoing OEM manufacturing relationship.
• EA PharmaminorStrategic or Co-development PartnerPartnership established as part of globalization goals with leading multinational pharmaceutical companies.
• DKSH (Distribution Services)minorChannel Partner/ Reseller/ DistributorDistribution services partner for pharmaceutical products.

Scale indicators7 records

Recent moves6 records

Expansion highlights4 records

Others

• DKSH: Market expansion services company providing distribution and logistics services for pharmaceutical, consumer goods, and other products across Asia. Ampharco's distribution partner; comparable in pharmaceutical supply chain and warehousing capabilities in Vietnam.

Direct peers

• DHG Pharmaceutical (Hau Giang Pharma): One of Vietnam's largest domestic pharmaceutical manufacturers with broad generic portfolio and nationwide distribution. Comparable to Ampharco in therapeutic category breadth, manufacturing scale, and Vietnamese market focus.
• Pymepharco: Vietnamese pharmaceutical manufacturer with similar product breadth across multiple therapeutic categories, hospital tender participation, and wholesale distribution across Vietnam.
• Traphaco: Leading Vietnamese pharmaceutical manufacturer specializing in branded generic and traditional medicine products. Comparable business model with domestic manufacturing, hospital tender participation, and pharmacy distribution.
• Mekophar: Vietnamese pharmaceutical manufacturer producing branded generics and OTC products across multiple therapeutic categories. Comparable manufacturing, distribution, and Vietnamese market positioning.
• Domesco: Vietnamese pharmaceutical manufacturer with manufacturing facilities, branded generics, and nationwide distribution. Directly comparable in therapeutic portfolio breadth and Vietnamese market operations.
• Imexpharm: Vietnamese pharmaceutical company operating manufacturing facilities, distribution, and branded generic products across multiple therapeutic categories. Comparable in scale and domestic market focus.

Broad incumbents

• Sanofi: Global multinational pharmaceutical company and long-standing OEM partner of Ampharco since 2012. Comparable in advanced manufacturing standards and pharmaceutical development, but operates at much larger scale across global markets.
• EA Pharma: Multinational pharmaceutical company with established partnership with Ampharco, focused on branded pharmaceutical distribution across Asia. Comparable in international pharmaceutical standards and Asian market presence.
• Servier (Les Laboratoires Servier): French multinational pharmaceutical group that signed a 2025 technology transfer agreement with Ampharco for original brand medicine production in Vietnam. Comparable in pharmaceutical manufacturing expertise and cardiometabolic focus, but at significantly larger global scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ampharco